Immunotherapy for Glioblastoma: A Focus on PD-1/PD-L1 Inhibitors

Area of Science:

• Neuro-oncology
• Immunotherapy
• Cancer Research

Background:

• Glioblastoma is a lethal brain tumor with poor prognosis.
• Immune checkpoint inhibitors (ICIs) show variable efficacy in cancer treatment.
• PD-1/PD-L1 immunotherapy faces challenges in glioblastoma due to the immunosuppressive brain microenvironment and blood-brain barrier.

Purpose of the Study:

• To summarize factors limiting PD-1/PD-L1 immunotherapy efficacy in glioblastoma.
• To explore strategies for enhancing immunotherapy response in glioblastoma.
• To review advancements in overcoming the blood-brain barrier and the role of imaging in glioblastoma treatment.

Main Methods:

• Literature review of preclinical and clinical studies on glioblastoma immunotherapy.
• Analysis of resistance mechanisms to PD-1/PD-L1 therapy.
• Investigation of combination therapies and blood-brain barrier modulation techniques.

Main Results:

• Intratumoral heterogeneity and the immunosuppressive tumor microenvironment are major resistance factors.
• Combination therapies, including agents targeting the tumor microenvironment, show promise.
• Blood-brain barrier penetration and molecular imaging are crucial for therapeutic enhancement.

Conclusions:

• Improving glioblastoma immunotherapy requires addressing resistance mechanisms and enhancing drug delivery.
• Combination strategies and advanced imaging techniques are vital for future treatment paradigms.
• Further research into blood-brain barrier modulation and radiogenomics is essential for advancing glioblastoma treatment.